Thank you for submitting your research manuscript to The EMBO Journal editorial office. I did now receive reports from two referees. In the interest of efficient proceedings and due to their overlapping assessment of your work, I am in the position to come to a conclusion on your paper. Both referees appreciate the interesting findings on the Aub-Tudor-Ago complex that indicates a contribution in the piRNA-processing. However, to assure not only complementation/confirmation of similar results here in Drosophila, both also suggest to go a step further by characterizing piRNA's and transposon silencing, if not even a more thorough characterization of the putative piRNA precursors and gaining more insight into role of the Aub-Tudor-Ago complex defining specificity. Although this might mean significant more work, it would certainly warrant true novel insight in the reported observations that would also benefit the overall perception and impact of your study. Therefore, we would highly recommend to pursue these lines of research before submitting a thoroughly revised version of your paper. Depending on the amount of already available additional results, we would also be able to extend the deadline for the revision upon request to ensure sufficient time for necessary experimentation.
1.
The authors claim that Tudor, Aub and Ago3 can form a trimeric complex. This statement is based on the observation that a sDMA peptide derived from Ago3 pulls down Tudor as well as Aub. However, it also pulls down Ago3. Would that mean that Tudor is a larger platform with space for multiple Ago3 and/or Aub molecules? It is also unclear why Ago3 is not co-immunoprecipitated with Aub in Figure 1D and why anti-Ago3 antibodies do not co-immunoprecipitate Tudor in Figure  5A ? Does such a complex exist in dprmt5-/-flies? Without further testing, these findings are speculative and even inconsistent.
2.
The use of a sDMA-specific antibody in Figure 1C (lower panel) and 5A (lower panels) is not specified in the text. This should be included.
3.
The identity of the larger RNA smear that co-immunoprecipitate with anti-Tudor antibodies is unclear. Before speculating on piRNA precursors, the authors should try to find out what it actually is. The authors could either clone and sequence the longer RNA species or try to get an idea about their sequence by PCR with suitable primers. The quality of the Northern blot shown in Figure  4B (right panel) is rather low and should be repeated.
4.
Is Tudor an RNA binding protein? Is methylation required for RNA binding? The antiTudor immunoprecipitations should be performed in dprmt5-/-flies. 5.
Page 12: "...These results indicate that loss of tudor function significantly affects the contents of piRNAs loaded onto Aub and Ago3." There is no difference at all on minisatellite#1 piRNA binding to Ago3 in tud-/-and control flies ( Figure 5D , right panel). 6.
The authors state in the text (top, page 13): "...Northern blot analysis for roo#4 piRNA confirmed that piRNA loading onto Aub was severely lowered by dprmt5 mutations ( Figure 6B )." However, total roo#4 piRNA levels are severely lowered a well. Conclusions on Aub loading are therefore not possible. The same holds true for Tudor mutations that are shown in Figure 5C .
Referee #2 (Remarks to the Author):
Several recent publications (Kirino 2009 , Reuter 2009 , Wang 2009 , Vasileva 2009 , Thomson 2008 and, while this manuscript was under review, Vagin 2009) have reported on symmetric arginine dimethylation (sDMA) of Piwi family proteins in mouse, xenopus and flies, and/or Tudor proteins as Piwi interaction partners whose binding depends on sDMAs. From these reports, a model emerged in which Tudor proteins determine, through an unknown mechanism, the identity and amount of piRNAs with which Piwis are associated.
The work by Nishida et al. extends on this theme, providing additional insight on how these interactions occur in flies. In particular, whereas the above reports primarily focused on mouse, the data available for fly was much more limited. Nishida et al. thus show for the first time that Tudor (Tud) is the fly Tudor protein that binds to methylated Ago3, Aub. Using mass spec, they directly confirm methylation of specific arginines in Aub that had already been implicated by mutagenesis studies by Kirino et al. They also provide evidence that Tudor might be able to bind both Ago3 & Aub at the same time, potentially serving as a docking platform for the ping-pong cycle of piRNA amplification -however, this part of the manuscript is not convincing (see below). Moreover, when probing RNA isolated by Tudor IP for presence of roo piRNAs, Nishida et al. observe a signal corresponding to longer RNAs, that is not seen with Aub IPs. Nishida et al. speculate that this signal (which is also seen in total lysates from ovaries lacking Tud) derive from piRNA precursor-like molecules -an intriguing notion that, however, requires more validation. Finally, the authors conclude that Tud participates in a quality control mechanism that prevents inappropriate entry of cytoplasmic RNAs into Aub and Ago3, but this is based on looking at association of only one piRNA each.
Taken together, the more strongly supported findings presented by Nishida et al. largely mirror those from the earlier and concurrent manuscripts, and provide welcome validation and fill in some gaps. Given the current broad interest in small RNAs and the overall good quality of the data, publication in The EMBO J might be considered, although this would minimally require a more comprehensive and convincing documentation of the altered association of PIWIs with piRNAs and its consequence for transposon silencing in the absence of Tud (see below). I would also be much more enthusiastic about endorsing publication if the authors could provide better support for at least some of their more unexpected and intriguing findings, i.e., existence of the Aub-Tud-Ago3 trimeric complex and binding of piRNA precursors to Tud as part of the piRNA biogenesis process.
Major points:
1.
The conclusion that Tudor can bind Aub and Ago at the same time is based on pulldown experiments (Fig. 3B ) using the respective methylated peptides. By contrast, IP of full-length Aub fails to show co-IP of Ago3 (Fig. 2D) , and no data are provided for the reciprocal experiment. These data thus rather seem to suggest that the trimeric complex observed in the peptide pulldown experiment is an artifact. As a matter of fact, Ago3 IP even fails to co-IP detectable amounts of Tud ( To support the model that an Aub-Tudor-Ago complex exists, the authors should do the following experiments: IP endogenous Aub and Ago3 and show that the respective other PIWI protein is coIPed. Further show that this interaction depends on Tudor by demonstrating loss of interaction when using Tud mutant ovaries as starting material. These findings would significantly enhance this manuscript. If these experiments do not provide the expected results (which Fig. 2D suggests is what will happen), the authors need to acknowledge the discrepancy between the peptide pulldown and IP data and point out that the IP data argue against the idea that a functionally relevant trimeric complex exist in vivo.
2.
The idea that Tudor can bind to piRNA precursors and present them to Piwi proteins for processing and loading is very intriguing, but so far only based on a smeary signal on a northern blot. Moreover, what is labeled as 'pre-piRNA-like' in Fig. 4B (namely multiple bands extending from 200 to > 400 nt), appears to be present, at least in part, also in total lysates of wild-type and tud mutant ovaries in 5C and D (bands around 400 nt), but here the precursors are either not labeled (D) or labeled at between 50-100 nt (C; i.e., clearly distinct). Of note, the band at 400 is seen in 5D even though a probe against a different set of piRNAs is used, suggesting that it might represent a nonspecific signal. This should be discussed. Moreover, the authors should clone and sequence these putative piRNA precursors to confirm their identities. 5' and 3' RACE analysis would be particularly useful.
3.
What is the functional consequence for transposon silencing when piRNAs are misloaded in the Tud mutant?
4.
Is roo#4 the only affected piRNA? It is rather brave to build a whole model of Tudor acting as a quality control mechanism or gatekeeper for piRNA entry into PIWIs on only one example for AGO3 and two for Aub, particularly, when only one of these, roo #4, displays an effect. (Athough the abstract claims that the amounts of transposon derived piRNAs associated with Aub and AGO3 were decreased by tud mutations, this is actually not true for AGO3, for which Fig 5D reveals no alteration, as also stated on p.12!)
The model does not appear unreasonable, but really owes most of its support to the work of others (chiefly that by Reuter et al.), not the current manuscript. Deep sequencing would do a nice job here to provide more definitive evidence for a global piRNA deregulation and show that indeed "unnatural" piRNAs, from regular cytoplasmic transcripts, are loaded into PIWI proteins in the absence of Tud. From the data presented here, the authors CANNOT conclude that the greater abundance of total piRNAs seen with Aub, AGO3 IPs in the absence of Tud or dPRMT5 reflects aberrant processing of cytoplasmic transcripts -equally likely, these could derive from other transposons, not tested. The authors have the expertise for deep sequencing analysis as demonstrated in their previous work, so it should be straightforward for them to collect these data.
5.
The authors repeatedly (e.g., abstract, p.12, p.15, first paragraph) invoke a function of Tud, PRMT5 in "piRNA loading" -this is not supported by the available data and should be modified to a more neutral interpretation that these proteins affect the association of Piwi proteins with piRNA. (It remains to be determined whether it is the loading step that is affected or perhaps the piRNA stability or release.) In particular, on p. 12, first paragraph, the authors claim that loading of roo#4 piRNA onto Aub was reduced in the absence of Tudor, but the tudor mutation also causes a drastic reduction in the levels of this piRNA in total. There is thus no need to to invoke a loading defect to explain less efficient IP with Aub. If anything, "loading" into Ago3 seems to be much more efficient in the absence of Tud: although total minisatellite #1 piRNA levels are greatly decreased in the tud mutant lysate, its abundance in Ago3 co-IP is unaltered.
6.
The omission of relevant citations throughout this manuscript is aggravating. For instance, Thomson et al. (Mech Dev, 2008) already showed co-IP of Aub with Tudor (without providing evidence for a direct interaction). In mouse, Vasileva et al. (Curr Biol 2009 ) also showed that Tdrd6 can interact with Piwis -with Tdrd6 being the putative direct orthologue of fly Tud, making the finding that Tud and not Tdrd1 interacts with Aub less surprising than one would expect from the authors emphasis. These findings must be acknowledged (e.g., on p.8). Thomson et al. also reported Aub and Tudor localization data, this should be discussed on p.13.
7.
Amounts loaded (i.e., per cent input and IP, respectively) need to be specified for all IP experiments so that the extent/stability of interaction can be gauged.
8.
The nature of all relevant mutant alleles should be indicated -are these nulls, partial loss of function?
Minor comments:
1.) p.5, last sentence: meaning unclear -how does dPRMT5 support the inference?
2.) P.6, para 2: "Tud, Aub and AGO3 are able to form a large, heteromeric complex, which also contains pre-piRNA-like molecules" Even assuming that the trimeric complex exists, the authors do not provide any evidence that it is actually this complex that associates with the putative piRNA precursors -in fact given that these molecules are not detected in Aub IPs (Fig. 4B ), this appears rather unlikely; please modify sentence.
3.) P.7, first para, last sentence: Unclear -how was sDMA modification confirmed?
4.) P. 10, last sentence: explain why specifically the levels of roo piRNAs are investigated 5.) P. 12, last sentence: redundant with p.8 6.) P. 16, last para: "total mount" should be "amount" 7.) P. 17, para 2: "However, the specificity shown by the northern blot analysis indicates that they must correspond to piRNA precursors ..." I disagree, at best it could be said that the signal MIGHT correspond to such precursors. Following sentence: I do not see any data that show that Tud passes RNAs "without fail" to Piwi proteins Thank you very much for your response and for your thoughtful suggestions for our manuscript entitled "Functional involvement of Tudor and dPRMT5 in the piRNA processing pathway in Drosophila germlines" by Kazumichi M. Nishida et al.
We also appreciated the helpful and thoughtful comments of the reviewers and the extension of the due date for the revision submission.
We have now revised our manuscript in accordance with your suggestions and the reviewers' comments. Please note that Toutai Mituyama has been added to the list of authors. Our detailed point-by-point responses to the comments of the reviewers are as follows:
The Figure 3B in 2 the revision). We also show that anti-AGO3 immunoprecipitates contain Aub and Tudor ( Figure 3C in the revision). These data support the idea that Tudor can bind Aub and AGO3 at the same time in ovaries. In parallel, however, we found that Tud is not required for the association between Aub and AGO3; because Aub and AGO3 can associate even in tud mutant ovaries (Supplementary Figure 3B in the revision). Based on these observations and on peptide pull-down assay data, we concluded that Tud, Aub and AGO3 are able to form not only a ternary, or possibly even a larger complex, but also other complexes containing Tud, Aub and AGO3 in different combinations. We have amended the revised version of the manuscript in respect of these observations. Figure 1D and why anti-Ago3 antibodies do not co-immunoprecipitate Tudor in Figure 5A ? Does such a complex exist in dprmt5-/-flies? Without further testing, these findings are speculative and even inconsistent.
It is also unclear why Ago3 is not co-immunoprecipitated with Aub in
We have now been able to show that AGO3 exists in the anti-Aub immunoprecipitates. We have also detected Tud in the anti-AGO3 immunoprecipitates. These new results appear in the revised manuscript.
The use of an sDMA-specific antibody, SYM11, in Figures 2C and 5A, was specified in the figure legends. As suggested by the reviewer, we performed RT-PCR to show that the anti-Tud immunoprecipitates included fragments of transposon transcripts that likely correspond to piRNA precursors. Importantly, the PCR products were not detected with negative control, non-immune IgG. These data were added as Supplementary Figure 4 in the revised manuscript.
The quality of the Northern blot shown in Figure 4B (right panel) is rather low and should be repeated.
We repeated the experiment using a slightly longer RNA probe and obtained a clearer result, which now replaces with the original data in Figure 4B .
Is Tudor an RNA binding protein? Is methylation required for RNA binding? The anti-Tudor immunoprecipitations should be performed in dprmt5-/-flies.
We performed immunoprecipitation of Tud from dprm5 mutant ovaries. However, the mutant ovaries were tiny. In addition, anti-Tud antibodies were not suited for immunoprecipitation; thus, we failed to obtain a sufficient amount of Tud to examine the associated RNAs. The Tudor domain has previously been predicted to be an RNA-binding domain because it was found in many kinds of RNA-binding proteins (Ponting, TIBS 1997) . However, supporting data have not been generated since this observation. We believe that the methylation of arginine residues of Aub and AGO3 is not required for RNA-binding because even in dprmt5 mutant ovaries Aub and AGO3 were detected to be associated with piRNAs. Figure 5D , right panel).
As the reviewer pointed out, northern blot data shown in Figure 5D ( Figure 6D in the revision) indicate that there is no apparent difference in minisatellite#1 piRNA binding to AGO3 in tud mutant and wt control. However, the amount of total piRNAs associated with AGO3 in wt ovaries were much less (about a quarter) compared with that in tud mutant ovaries ( Figure 5B ). Thus, we concluded that loss of tud function significantly affects the polulation of piRNAs associated with Aub and AGO3. A series of northern blot analyses, along with deep-sequencing analysis of Aubassociated piRNAs in tud mutant and wt control, later clarified that the population of transposonderived piRNAs associated with Aub are greatly affected by loss of tud function. These new data are now included in the revised manuscript ( Figure 6 and 4 Supplementary Figure 5) . Figure 5C .
roo#4 piRNA can be loaded onto Piwi (Nishida et al. RNA 2007) . However, the total mount of Piwi in ovaries is much less compared with that of Aub (M.K.N. unpublished data). The severely lowered level of roo#4 piRNA in the 'total' lane merely reflects the severely lowered level of roo#4 piRNA associated with Aub.
Reviewer #2:
The conclusion that Tudor can bind Aub and Ago at the same time is based on pulldown experiments (Fig. 3B) Figure 3C and Supplementary Figure 3B) . In parallel, however, we found that Tud is not required for association between Aub and AGO3, because Aub and AGO3 can associate with each other even in tud mutant ovaries (Supplementary Figure 3B) . Based on these observations and peptide pull-down assay data, we concluded that Tud, Aub and AGO3 are able to form not only a ternary, or possibly even a larger complex, but also other complexes containing Tud, Aub and AGO3 in different combinations. With respect to these observations, we have amended the revised version of the manuscript.
It is also not clear to me whether the detection of Aub by western blotting in Aub-sDMA peptide pulldown means that endogenous full-length Aub co-IPs with the peptide? Is there any evidence that Aub can homodimerize?
We have performed pull-down assays form ovary lysate using GST-Aub (full-length) under the same conditions we utilized for the peptide pull-down assays. We did not detect Aub by western blot analysis using anti-Aub in the bound fraction (M.K.N. unpublished data). Thus, it is likely that Aub does not homodimerize. From the results of the peptide pull-down assays, we concluded that Tud, Aub and AGO3 are able to form a ternary or even a larger complex in ovaries.
To support the model that an Aub-Tudor-Ago complex exists, the authors should do the following experiments: IP endogenous Aub and Ago3 and show that the respective other PIWI protein is coIPed. Further show that this interaction depends on Tudor by demonstrating loss of interaction when using Tud mutant ovaries as starting material. These findings would significantly enhance this manuscript. If these experiments do not provide the expected results (which Fig. 2D suggests is what will happen), the authors need to acknowledge the discrepancy between the peptide pulldown and IP data and point out that the IP data argue against the idea that a functionally relevant trimeric complex exist in vivo.
This particular point is strongly related to the first comment from the reviewer. As we mentioned above, we performed the immunoprecipitation experiments and showed that the anti-Aub immunoprecipitates contain Tud and AGO3. We have also done another IP experiment, where the anti-AGO3 immunoprecipitates contained Aub and Tudor. These data support the idea that Tudor can bind Aub and AGO3 at the same time in ovaries. These data are now shown in the revised manuscript ( Figure 3C and Supplementary Figure 3B ). At the same time, we found that Tud is not required for the association between Aub and AGO3; because Aub and AGO3 can associate with each other even in tud mutant ovaries (Supplementary Figure 3B) . Based on these observations and on peptide pull-down assay data, we concluded that Tud, Aub and AGO3 are able to form not only a ternary, or possibly even a larger complex, but also other complexes containing Tud, Aub and AGO3 in different combinations. As has been suggested by the other reviewer (Reviewer #1), we performed RT-PCR to show that the immunoprecipitates with anti-Tud antibodies included fragments of transposon transcripts that likely correspond to piRNA precursors. These data were added as Supplementary Figure 4 in the revised manuscript. We believe that the smeary band in the total RNA fraction of tud mutant ovaries ( Figure  6A ) corresponds to pre-piRNA precursors. Without tud function, the precursors are not properly processed; thus, these signals can be detected in tud ovaries. AGO3-associated piRNA ( Figure 6D ) is not an abundant piRNA, hence longer exposure times were required to show the signals. This may be the reason why we see the piRNA precursor-like signals in the total RNA fractions of both wt and tud ovaries. Cloning and sequencing of these molecules are in progress in our laboratory.
What is the functional consequence for transposon silencing when piRNAs are misloaded in the Tud mutant?
The Kai group showed in their paper that in tud mutants, the expression levels of transposons are not much affected compared with those in wt (Lim and Kai, PNAS 2007) . Actually, Thompson and Lasko reported that "around 15% of embryos produced by tud-null females have normal somatic patterning and hatch to become sterile adults" (Thompson and Lasko, Mech Dev. 2004 ). Thus, piRNA misloading onto Aub and AGO3 certainly occurs in tud mutants and it causes defects in fertility to some extent, but the effects may not be so large.
Is roo#4 the only affected piRNA? It is rather brave to build a whole model of Tudor acting as a quality control mechanism or gatekeeper for piRNA entry into PIWIs on only one example for AGO3 and two for Aub, particularly, when only one of these, roo #4, displays an effect. (Athough the abstract claims that the amounts of transposon derived piRNAs associated with Aub and AGO3 were decreased by tud mutations, this is actually not true for AGO3, for which Fig 5D reveals no alteration, as also stated on p.12!).
We performed deep-sequencing of piRNAs associated with Aub in wt and tud mutant ovaries and found that changes in piRNA loading can be observed for various kinds of transposons. Thus, we conclude that Tud acts as a quality controller for piRNA entry into PIWI proteins. These data are now added to the revised manuscript as Supplementary Figure 5 . This point is largely related to the one above. Through deep-sequencing analysis of piRNAs associated with Aub in wt and tud mutant ovaries, we found that changes in piRNA loading can be observed for various kinds of transposons but not for rRNA, tRNA and other RNAs. Thus, the situation is clearly different from the one observed in the mouse tdrd1 mutant. We have described these new deep-sequencing findings in the revised text.
The authors repeatedly (e.g., abstract, p.12, p.15 We have recently shown by performing RT-PCR that the immunoprecipitates with anti-Tud antibodies contain pre-piRNA-like molecules. Previous reports show that the association of Sm proteins through their sDMAs with Tudor domain-containing SMN protein concomitantly recruits U snRNA and by such mechanisms U snRNP is efficiently assembled. Thus, the PRMT5-SMN-system serves as a chaperone system that prevents the mis-assembly of Sm proteins to non-target RNA and also prevents Sm protein aggregation. Recently, Reuter et al. (Reuter et al, NSMB 2009) reported that "Mili piRNAs devoid of Tdrd1 accept the entry of abundant cellular transcripts into the piRNA pathway and accumulate piRNAs with a profile that is drastically different from that of the wild type". These observations and earlier reports suggest that Tud and dPRMT5 are most likely to be involved in piRNA loading onto (or association with) PIWI proteins but are not likely to be involved with piRNA stability or release. However, to provide a neutral interpretation, we changed the relevant sentences in the revised text.
In roo#4 piRNA can be loaded onto Piwi (Nishida et al, RNA 2007) . However the total amount of Piwi in ovaries is much less compared with that of Aub. Thus, the severely lowered level of roo#4 piRNA in the 'total' lane merely reflects the severely lowered level of roo#4 piRNA loading onto Aub. Thomson et al. (Mech Dev, 2008) We have now added the references in the revised manuscript. We thank the reviewer for noticing these omissions.
The omission of relevant citations throughout this manuscript is aggravating. For instance,
We have indicated the information in the Materials and Methods section.
The nature of all relevant mutant alleles should be indicated -are these nulls, partial loss of function?
The nature of all relevant mutant alleles is now indicated in the revised text (see the Materials and Methods section).
p.5, last sentence: meaning unclear -how does dPRMT5 support the inference?
We amended this part in the revised text to clarify our point.
P.6, para 2: "Tud, Aub and AGO3 are able to form a large, heteromeric complex, which also contains pre-piRNA-like molecules" Even assuming that the trimeric complex exists, the authors do not provide any evidence that it is actually this complex that associates with the putative piRNA precursors -in fact given that these molecules are not detected in Aub IPs (Fig. 4B ), this appears rather unlikely; please modify sentence.
We have performed RT-PCR to show that the anti-Tud immunoprecipitates included fragments of transcripts that likely correspond to piRNA precursors (Supplementary Figure 4) . These molecules were not detected in the anti-Aub immunoprecipitates because the complex contains far fewer Tud.
P.7, first para, last sentence: Unclear -how was sDMA modification confirmed?
We deleted the sentence "the sDMA modification on R11, R13, and R15 of Aub was confirmed" from the revised text because we considered it to be unnecessary.
P. 10, last sentence: explain why specifically the levels of roo piRNAs are investigated.
We chose roo piRNAs to detect in the experiments because roo piRNAs were extensively analyzed by microarray analysis in Vagin et al. (Figure 4A in Vagin et al, Science 2006) .
P. 12, last sentence: redundant with p.8.
We removed the redundant sentence from the revised text.
P. 16, last para: "total mount" should be "amount".
We changed 'total mount' to 'total amount' in the revised text. We changed these sentences in the revised manuscript, in accordance with the reviewer's comment. We now use arrows and arrow heads in the revised manuscript to indicate the features mentioned in the legend. We again checked the intensity of the corresponding bands and confirmed that the intensity of the Aub band in the anti-Aub x 1/5 lane is about the same as that in the anti-Tud x 1 lane. Thus, our conclusion "the Aub amount in Aub IP (x 1) is approximately five times more than the Aub amount in Tud IP (x 1)" should be reasonable. We changed "Affects" to "Effects", according to this comment.
We recently analyzed the peptide modification status of AGO3 in ovaries and found that R4, R68 and R70 of AGO3 have the sDMA modification. These results accompany the revised manuscript as Supplementary Figure 2 .
We hope that after the revisions we have made, the manuscript is now in a form suitable for publication in EMBO Journal.
Again, we thank you for your kind consideration.
2nd Editorial Decision 09 November 2009
Your revised manuscript has now been re-assessed by an expert scientist that essentially supports publication. S/he still brought up two issues: the first relates to potential further biochemical support for the proposed complex formation, the second a simple note on presentation. I kindly ask you to attend to those in a little more detail and submit an ultimate version of your paper as soon as possible.
Yours sincerely, Editor EMBO Journal
REFEREE REPORT
In page 3 (response), the authors say: "In addition, anti-Tud antibodies were not suited for immunoprecipitation". However, in page 9 (~half) of the paper, Results section, they say that "Immunoprecipitation from wild-type ovary lysates using anti-Tud antibodies confirmed the association of Aub with Tud ( Figure 2D ). How do you reconcile this? I understand that mutant ovaries are smaller, but the antibody should work anyway.
In page 4 (response), addressing reviewer n∫2, the authors say "we repeated the IP experiments and showed that the anti-Aub immunoprecipitates contain Tud and AGO3". I wonder why they can show it now but couldn't in the original submission. If IPs are problematic, I would ask the authors for a simply gradient centrifugation or a gel exclusion chromatography, followed by a triple western blot, where they should obtain fractions where the three proteins should be together.
Finally I would suggest the authors to differentiate the last part of the Abstract from the last paragraph of the Intro. They have done a simple copy-paste, which doesn't look good. Thank you very much for your response and for your kind suggestions for our manuscript entitled "Functional involvement of Tudor and dPRMT5 in the piRNA processing pathway in Drosophila germlines" by Kazumichi M. Nishida et al. We also appreciated again the thoughtful comments of the reviewer.
We have now re-revised our manuscript in accordance with the reviewer's comments. Our detailed point-by-point responses to the comments of the reviewers are as follows:
Reviewer:
We found through our study that anti-Tudor antibodies we used, both polyclonals that have been provided from other groups and monoclonals that we newly produced in this study, work for immunoprecipitation only when sufficient concentration and volume of ovarian lysates were available. However, when the concentration and volume of ovarian lysates were so low, as in the case of the dprmt5 mutants of which ovaries were so small and thus we could not prepare lysates suited for the immunoprecipitation, anti-Tud antibodies did not immunoprecipitate the antigen. This is just the property of the anti-Tud antibodies we have, we believe.
In page 4 (response), the authors say "we repeated the IP experiments and showed that the anti-Aub immunoprecipitates contain Tud and AGO3". I wonder why they can show it now but couldn't in the original submission.
As mentioned in the Materials and Methods section of the revised manuscript, we lately produced monoclonal antibodies for Tud. By utilized the antibodies in the IP/western experiments, we could show that anti-Aub immunoprecipitates contain Tud together with AGO3. Apparently, the monoclonal antibodies work slightly better than polyclonals for western blot analysis, but not for immunoprecipitation, as mentioned above.
If IPs are problematic, I would ask the authors for a simply gradient centrifugation or a gel exclusion chromatography, followed by a triple western blot, where they should obtain fractions where the three proteins should be together.
We performed sucrose gradient sedimentation experiments and found that Tud, Aub and AGO3 cosedimented even in relatively heavier fractions. The data have now been included as Supplementary Figure 3B in the re-revision.
Finally I would suggest the authors to differentiate the last part of the Abstract from the last paragraph of the Intro. They have done a simple copy-paste, which doesn't look good.
We have now amended the last sentence in the Introduction in the re-revision.
We hope that after the second revisions we have made, the manuscript is now in a form suitable for publication in EMBO Journal.
